BioSkryb Genomics and Cooper Surgical Ink Multi-Year Deal to Accelerate Clinical Discovery and Diagnostics in Women's Reproductive Health
businesswire.com
news
2022-10-18 00:00:00

DURHAM, N.C.--(BUSINESS WIRE)--BioSkryb Genomics, a pioneer in developing scientifically advanced single-cell analysis molecular tools, today announced a multi-year agreement with Cooper Genomics, a leader in the reproductive health market, to license BioSkryb's proprietary genomic amplification technology. Cooper Genomics will utilize the BioSkryb technology to enhance their preimplantation genetic testing (PGT) capabilities. The agreement will also permit Cooper Genomics to market and distribute the BioSkryb technology for the PGT and women's reproductive health market globally.
